DE69434211D1 - Phenylacetate und derivate, allein oder in kombination mit anderen verbindungen, zur behandlung von neoplastischen und anderen erkrankungen - Google Patents
Phenylacetate und derivate, allein oder in kombination mit anderen verbindungen, zur behandlung von neoplastischen und anderen erkrankungenInfo
- Publication number
- DE69434211D1 DE69434211D1 DE69434211T DE69434211T DE69434211D1 DE 69434211 D1 DE69434211 D1 DE 69434211D1 DE 69434211 T DE69434211 T DE 69434211T DE 69434211 T DE69434211 T DE 69434211T DE 69434211 D1 DE69434211 D1 DE 69434211D1
- Authority
- DE
- Germany
- Prior art keywords
- phenylacetate
- methods
- derivatives
- alone
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/135,661 US5635532A (en) | 1991-10-21 | 1993-10-12 | Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia |
US135661 | 1993-10-12 | ||
US207521 | 1994-03-07 | ||
US08/207,521 US5605930A (en) | 1991-10-21 | 1994-03-07 | Compositions and methods for treating and preventing pathologies including cancer |
PCT/US1994/011492 WO1995010271A2 (en) | 1993-10-12 | 1994-10-12 | Phenylacetate and derivatives alone or in combination with other compounds against neoplastic conditions and other disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69434211D1 true DE69434211D1 (de) | 2005-02-03 |
DE69434211T2 DE69434211T2 (de) | 2005-12-15 |
Family
ID=26833540
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69434211T Expired - Lifetime DE69434211T2 (de) | 1993-10-12 | 1994-10-12 | Phenylacetate und derivate, allein oder in kombination mit anderen verbindungen, zur behandlung von neoplastischen und anderen erkrankungen |
DE69435086T Expired - Lifetime DE69435086T2 (de) | 1993-10-12 | 1994-10-12 | Phenylacetate und Derivate, allein oder in Kombination mit anderen Verbindungen, zur Behandlung von neoplastischen und anderen Erkrankungen |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69435086T Expired - Lifetime DE69435086T2 (de) | 1993-10-12 | 1994-10-12 | Phenylacetate und Derivate, allein oder in Kombination mit anderen Verbindungen, zur Behandlung von neoplastischen und anderen Erkrankungen |
Country Status (15)
Country | Link |
---|---|
US (4) | US5605930A (de) |
EP (2) | EP1523982B1 (de) |
JP (5) | JP3628694B2 (de) |
AT (2) | ATE285760T1 (de) |
AU (1) | AU702051B2 (de) |
CA (1) | CA2173976C (de) |
DE (2) | DE69434211T2 (de) |
DK (1) | DK1523982T3 (de) |
ES (2) | ES2233931T3 (de) |
HK (1) | HK1077204A1 (de) |
IL (1) | IL111251A (de) |
NZ (1) | NZ275673A (de) |
PT (2) | PT725635E (de) |
SI (1) | SI1523982T1 (de) |
WO (1) | WO1995010271A2 (de) |
Families Citing this family (113)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6204370B1 (en) * | 1992-03-11 | 2001-03-20 | Institute Of Virology, Slovak Academy Of Sciences | MN gene and protein |
US6407082B1 (en) | 1996-09-13 | 2002-06-18 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of a vitamin D compound |
CA2174737C (en) * | 1993-10-29 | 2008-04-22 | Douglas V. Faller | Physiologically stable compositions of butyric acid, and butyric acid salts and derivatives as anti-neoplastic agents |
US5981597A (en) * | 1995-02-13 | 1999-11-09 | Trustees Of The University Of Pennsylvania | Differentiating agents for the treatment of inflammatory intestinal diseases |
US5705352A (en) * | 1995-02-27 | 1998-01-06 | Eli Lilly And Company | Multiple drug resistance gene of Aspergillus fumigatus |
US5932619A (en) * | 1995-10-13 | 1999-08-03 | Rush-Presbyterian, St. Luke's Medical Center | Method for preventing sexually transmitted diseases |
CA2257537C (en) * | 1996-06-11 | 2005-01-25 | Yeong Kuang Oon | Iterative problem solving technique |
US6197743B1 (en) | 1996-07-26 | 2001-03-06 | The Trustees Of Boston University | Compositions and methods for the treatment of viral disorders |
EP0969869A2 (de) * | 1996-07-26 | 2000-01-12 | Susan P. Perrine | Zusammensetzung enthaltend einen induzierenden wikstoff und einen antiviralen wirkstoff zur behandlung von viralen und zellulären störungen |
DE69726182T2 (de) * | 1996-12-11 | 2004-08-12 | Dana-Farber Cancer Institute, Inc., Boston | Methoden und pharmazeutische zusammenstellungen zur wachstumsverhinderung von tumorzellen enthaltend einen ppar-gamma agonisten und einen map kinase inhibitor |
CA2283333A1 (en) * | 1997-03-04 | 1998-09-11 | Charles E. Elson | Method of suppressing tumor growth with combinations of isoprenoids and statins |
US6110955A (en) * | 1997-03-11 | 2000-08-29 | Beacon Laboratories, Inc. | Metabolically stabilized oxyalkylene esters and uses thereof |
US5939455A (en) * | 1997-03-11 | 1999-08-17 | Beacon Laboratories, Inc. | Therapeutic augmentation of oxyalkylene diesters and butyric acid derivatives |
JPH10324639A (ja) * | 1997-03-21 | 1998-12-08 | Chugai Pharmaceut Co Ltd | Il−6アンタゴニストを有効成分として含有する感作t細胞関与疾患の予防・治療剤 |
WO1999007418A2 (en) * | 1997-08-11 | 1999-02-18 | Allergan Sales, Inc. | Sterile bioerodible implant device with improved biocompatability and method |
US6242196B1 (en) | 1997-12-11 | 2001-06-05 | Dana-Farber Cancer Institute | Methods and pharmaceutical compositions for inhibiting tumor cell growth |
WO1999040883A2 (en) * | 1998-02-11 | 1999-08-19 | Faller Douglas V | Compositions and methods for the treatment of cystic fibrosis |
US6258849B1 (en) * | 1998-07-23 | 2001-07-10 | Stanislaw R. Burzynski | Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate |
CA2344717A1 (en) * | 1998-09-28 | 2000-04-06 | The Johns Hopkins University | Adrenoleukodystrophy treatments and drug screening |
US6127419A (en) * | 1998-11-23 | 2000-10-03 | Burzynski; Stanislaw R. | Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis |
RU2252772C2 (ru) * | 1998-12-07 | 2005-05-27 | Экосмарт Текнолоджиз, Инк. | Состав для лечения рака и способ применения натуральных растительных масел |
EP1162884A4 (de) * | 1999-03-19 | 2002-07-24 | Vertex Pharma | Orale niedrigdosierte butyratzusammensetzungen |
AU4988100A (en) * | 1999-05-07 | 2000-11-21 | Brigham And Women's Hospital | Use of hmgcoa reductase inhibitors in the prevention of diseases whose pathogenesis is dependent on neovascularization |
US7576131B2 (en) * | 1999-06-04 | 2009-08-18 | Metabolex, Inc. | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia |
US6624194B1 (en) * | 1999-06-04 | 2003-09-23 | Metabolex, Inc. | Use of (−) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia |
US6262118B1 (en) | 1999-06-04 | 2001-07-17 | Metabolex, Inc. | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia |
US6403646B1 (en) | 1999-06-30 | 2002-06-11 | David H. Perlmutter | Method for the treatment of alpha-1-antitrypsin deficiency and related pathologies |
US6733779B2 (en) * | 1999-08-26 | 2004-05-11 | L. Dean Parks | Method of treating benign prostatic hyperplasia and other benign prostate conditions |
US6458838B1 (en) * | 1999-09-28 | 2002-10-01 | Johns Hopkins University | Adrenoleukodystrophy treatments |
US6864355B1 (en) | 2000-05-02 | 2005-03-08 | Yale University | Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain |
US6534537B2 (en) * | 2000-01-07 | 2003-03-18 | Kenneth Weisman | Use of HMG-COA reductase inhibitors to prevent and treat BPH |
US6723506B2 (en) | 2000-01-20 | 2004-04-20 | Brigham And Women's Hospital | Method of identifying PAX8-PPAR gamma-nucleic acid molecules |
WO2001066144A2 (en) * | 2000-03-08 | 2001-09-13 | Rhode Island Hospital, A Lifespan Partner | Antineoplastic combination comprising an inhibitor of angiogenesis and an inhibitor of dna topoisomerase i enzyme activity |
US6987131B1 (en) * | 2000-06-26 | 2006-01-17 | Burzynski Stanislaw R | Phenylacetic acid compositions for treating or preventing hypercholesterolemia |
CA2420576C (en) * | 2000-08-29 | 2005-06-14 | Nobex Corporation | Immunoregulatory compounds, derivatives thereof and their use |
US6538030B2 (en) | 2000-09-20 | 2003-03-25 | Yih-Lin Chung | Treating radiation fibrosis |
NZ526707A (en) * | 2000-11-28 | 2005-03-24 | Wyeth Corp | Use of SMARC nucleic acid and polypeptide expression analysis for the diagnosis and prognosis of prostate cancer |
BR0115728A (pt) | 2000-11-28 | 2003-09-23 | Wyeth Corp | Análise da expressão de ácidos nucléicos kiaa e polipeptìdeos úteis no diagnóstico e tratamento de cáncer de próstata |
AU2002241524A1 (en) * | 2000-11-28 | 2002-06-11 | Wyeth | Expression analysis of FKBP nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer |
US7033611B2 (en) * | 2001-02-23 | 2006-04-25 | Biora Bioex Ab | Matrix protein compositions for guided connective tissue growth |
US6495719B2 (en) | 2001-03-27 | 2002-12-17 | Circagen Pharmaceutical | Histone deacetylase inhibitors |
US7312247B2 (en) | 2001-03-27 | 2007-12-25 | Errant Gene Therapeutics, Llc | Histone deacetylase inhibitors |
US8026280B2 (en) | 2001-03-27 | 2011-09-27 | Errant Gene Therapeutics, Llc | Histone deacetylase inhibitors |
US7842727B2 (en) * | 2001-03-27 | 2010-11-30 | Errant Gene Therapeutics, Llc | Histone deacetylase inhibitors |
US8048924B2 (en) | 2001-08-29 | 2011-11-01 | Biocon Limited | Methods and compositions employing 4-aminophenylacetic acid compounds |
EP1291015A1 (de) | 2001-09-10 | 2003-03-12 | Lunamed AG | Darreichungsformen mit verlängerter Wirkstofffreisetzung |
MY131170A (en) * | 2002-03-28 | 2007-07-31 | Nissan Chemical Ind Ltd | Therapeutic agent for glomerular disease |
AU2003226730A1 (en) * | 2002-04-10 | 2003-10-20 | Haemato-Basics Gmbh | Vitamin combination for providing protection during the chemotherapy and/or radiotherapy of malignant tumours |
US20040229948A1 (en) * | 2002-04-12 | 2004-11-18 | Summar Marshall L. | Method for preventing hepatic encephalopathic episodes |
US8846039B2 (en) * | 2002-04-26 | 2014-09-30 | Asan Laboratories Company (Cayman), Limited | Method for ameliorating pruritus |
US6809118B2 (en) * | 2002-07-25 | 2004-10-26 | Yih-Lin Chung | Methods for therapy of radiation cutaneous syndrome |
US8163764B2 (en) * | 2002-04-26 | 2012-04-24 | Asan Laboratories Company (Cayman) Limited | Skincare methods |
US20030206946A1 (en) * | 2002-04-26 | 2003-11-06 | Yih-Lin Chung | Methods for therapy of connective tissue disease |
US8946295B2 (en) * | 2002-07-25 | 2015-02-03 | Sunny Pharmtech Inc. | Histone hyperacetylating agents for promoting wound healing and preventing scar formation |
US8883148B2 (en) * | 2002-04-26 | 2014-11-11 | Asan Laboratories Company (Cayman), Limited | Prevention of joint destruction |
US20060275370A1 (en) * | 2002-07-25 | 2006-12-07 | Yih-Lin Chung | Method and compositions for treatment of epithelial damage |
WO2003093798A1 (en) * | 2002-05-03 | 2003-11-13 | Thomas Jefferson University | Method to follow progression of kidney disease |
GB0210741D0 (en) * | 2002-05-10 | 2002-06-19 | Medical Res Council | Methods of therapy |
AU2003243272A1 (en) * | 2002-05-22 | 2003-12-12 | Errant Gene Therapeutics, Llc | Histone deacetylase inhibitors based on alpha-ketoepoxide compounds |
US7115563B2 (en) * | 2002-05-29 | 2006-10-03 | Insignion Holding Limited | Composition and its therapeutic use |
CA2506504A1 (en) * | 2002-11-20 | 2004-06-03 | Errant Gene Therapeutics, Llc | Treatment of lung cells with histone deacetylase inhibitors |
US7199259B2 (en) * | 2003-06-20 | 2007-04-03 | Metabolex, Inc. | Resolution of α-(phenoxy)phenylacetic acid derivatives |
US20050100537A1 (en) * | 2003-11-10 | 2005-05-12 | Evans Gregory S. | Methods and kits for reducing cellular damage, inhibiting free radical production, and scavenging free radicals in mammals |
US20050182122A1 (en) * | 2003-11-20 | 2005-08-18 | Bello Carlo L. | Method of treating abnormal cell growth using indolinone compounds |
US8617550B2 (en) * | 2003-12-19 | 2013-12-31 | Chugai Seiyaku Kabushiki Kaisha | Treatment of vasculitis with IL-6 antagonist |
TWI297606B (en) * | 2004-01-16 | 2008-06-11 | Nat Health Research Institutes | Cancer therapy |
CA3031283A1 (en) | 2004-01-22 | 2005-08-04 | University Of Miami | Topical co-enzyme q10 formulations and methods of use |
US20060084704A1 (en) * | 2004-01-28 | 2006-04-20 | Charles Shih | Methods and compositions for enhancing degradation of nuclear receptor transcription factors and uses thereof |
NZ548670A (en) * | 2004-01-28 | 2010-05-28 | Androscience Corp | Enhancement of anti-androgenic activity by a combination of inhibitors targeting different steps of a steroid-dependent gene activation pathway and uses thereof |
US20070264241A1 (en) * | 2004-02-25 | 2007-11-15 | Ekstrom Tomas J | Compounds for Enhanced Cancer Therapy |
RU2006145872A (ru) * | 2004-05-25 | 2008-06-27 | Метаболекс, Инк. (Us) | Замещенные триазолы в качестве модуляторов ppar и способы их получения |
EP1749000A4 (de) * | 2004-05-25 | 2009-12-30 | Metabolex Inc | Bicyclische substituierte triazole als ppar-modulatoren und verfahren zu deren herstellung |
PL1773767T3 (pl) | 2004-07-07 | 2016-07-29 | Biocon Ltd | Synteza azowo związanych związków immunoregulacyjnych |
US20060073213A1 (en) * | 2004-09-15 | 2006-04-06 | Hotamisligil Gokhan S | Reducing ER stress in the treatment of obesity and diabetes |
AU2005284798B2 (en) * | 2004-09-15 | 2012-02-02 | The President And Fellows Of Harvard College | Reducing ER stress in the treatment of obesity and diabetes |
CA2587013A1 (en) * | 2004-11-08 | 2006-05-18 | Errant Gene Therapeutics, Llc | Histone deacetylase inhibitors |
US8377918B2 (en) * | 2005-01-31 | 2013-02-19 | ACC Therapeutics Inc | Apigenin for chemoprevention, and chemotherapy combined with therapeutic reagents |
US7666676B2 (en) * | 2005-05-16 | 2010-02-23 | St. Joseph's Children's Hospital | Modulating cancer cell characteristics |
US20080292616A1 (en) * | 2005-08-19 | 2008-11-27 | Government Of The United Of America, Represented By The Secretary, Department Of Health And.... | Topical Formulations of Histone Deacetylase Inhibitors and Methods Using the Same |
KR100745821B1 (ko) * | 2005-09-23 | 2007-08-02 | 에스케이 주식회사 | 소디움 페닐부티레이트를 이용한 약물 또는 알코올 중독,또는 조울증의 예방 및 치료용 의약 조성물 |
US7714131B2 (en) * | 2005-09-23 | 2010-05-11 | Metabolex, Inc. | Process for the stereoselective preparation of (−)-halofenate and derivatives thereof |
JP2010515685A (ja) | 2007-01-08 | 2010-05-13 | アンドロサイエンス コーポレーション | (置換フェニル)−プロペナール部分を伴う化合物、その誘導体、生物学的活性およびその使用 |
US8710272B2 (en) | 2007-01-08 | 2014-04-29 | Androscience Corporation | Compounds with (1 E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof |
US9000222B2 (en) | 2007-01-08 | 2015-04-07 | Androscience Corporation | Compounds with (1E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof |
WO2008097491A2 (en) * | 2007-02-05 | 2008-08-14 | Wisconsin Alumni Research Foundation | Biomarkers of ionizing radiation response |
AU2008282749A1 (en) | 2007-07-31 | 2009-02-05 | Androscience Corporation | Compositions including androgen receptor degradation (ARD) enhancers and methods of prophylactic or therapeutic treatment of skin disorders and hair loss |
JP2009078977A (ja) * | 2007-09-25 | 2009-04-16 | Japan Health Science Foundation | 心筋の小胞体ストレス抑制剤 |
CA2711807A1 (en) * | 2008-01-08 | 2009-07-16 | Akthelia Pharmaceuticals | Agonists for antimicrobial peptide systems |
EP2271325A4 (de) | 2008-04-11 | 2011-11-09 | Cytotech Labs Llc | Verfahren und verfwendung zur einleitung von apoptose bei krebszellen |
US9063122B2 (en) * | 2008-10-17 | 2015-06-23 | Alfredo Gallegos | Biomodulators for treatment or prevention of disease |
WO2010105112A1 (en) * | 2009-03-11 | 2010-09-16 | Hemaquest Pharmaceuticals, Inc. | Detection of short-chain fatty acids in biological samples |
WO2010120931A2 (en) * | 2009-04-14 | 2010-10-21 | University Of Medicine And Dentistry Of New Jersey | E2f as a target for treatment of hormone refractory prostate cancer |
SG175855A1 (en) | 2009-05-04 | 2011-12-29 | Prometic Biosciences Inc | Substituted aromatic compounds and pharmaceutical uses thereof |
KR20180056816A (ko) | 2009-05-11 | 2018-05-29 | 베르그 엘엘씨 | 환경대사적 전환인자(조효소 q10)를 사용한 질환의 치료 방법 |
US20110086869A1 (en) | 2009-09-24 | 2011-04-14 | The Trustees Of Boston University | Methods for treating viral disorders |
CN102802412A (zh) | 2009-12-08 | 2012-11-28 | 海玛奎斯特医药公司 | 用于治疗红细胞病症的方法及低剂量方案 |
US20110245154A1 (en) | 2010-03-11 | 2011-10-06 | Hemaquest Pharmaceuticals, Inc. | Methods and Compositions for Treating Viral or Virally-Induced Conditions |
PL3443957T3 (pl) * | 2010-10-27 | 2021-05-04 | Liminal Biosciences Limited | Związki i kompozycje stosowane w leczeniu nowotworów |
JP6092844B2 (ja) | 2011-04-04 | 2017-03-08 | バーグ エルエルシー | 中枢神経系腫瘍の治療方法 |
EP2599482A1 (de) | 2011-11-30 | 2013-06-05 | Lunamed AG | Therapeutische Verwendung von niedrig dosiertem Glyceryl Tri-(4-Phenylbutyrat) |
EP2599767A1 (de) | 2011-11-30 | 2013-06-05 | Lunamed AG | Phenylbutyl-Derivate |
EP2607367A1 (de) | 2011-12-21 | 2013-06-26 | Lunamed AG | Glycerol-Phenyl-Butyrat-Derivate |
EP2607366A1 (de) | 2011-12-21 | 2013-06-26 | Lunamed AG | Glycerol-Phenyl-Butyrat-Ester |
CN103417521B (zh) * | 2012-05-15 | 2015-06-10 | 北京京朋汇药业研究发展有限公司 | 高原儿茶酸在制备抗肿瘤药物中的用途 |
EP2716167A1 (de) * | 2012-10-02 | 2014-04-09 | Lunamed AG | Nichtpharmazeutische Zusammensetzung mit kurzkettigen Fettsäuren |
WO2014138391A1 (en) * | 2013-03-06 | 2014-09-12 | The Johns Hopkins University | Targeting glutamine metabolism in brain tumors |
NZ713868A (en) | 2013-04-08 | 2021-12-24 | Berg Llc | Treatment of cancer using coenzyme q10 combination therapies |
SG10201907816RA (en) | 2013-09-04 | 2019-09-27 | Berg Llc | Methods of treatment of cancer by continuous infusion of coenzyme q10 |
JP7136807B2 (ja) | 2017-04-17 | 2022-09-13 | ザ・ユニバーシティ・オブ・シカゴ | ヒトの健康及び疾患の治療用途向けの短鎖脂肪酸の腸への送達用ポリマー材料 |
EP3976198A4 (de) | 2019-05-31 | 2023-07-19 | Viracta Subsidiary, Inc. | Verfahren zur behandlung von viral assoziiertem krebs mit histon-deacetylase-inhibitoren |
US11633554B1 (en) * | 2019-06-11 | 2023-04-25 | Luca Puviani | Adaptive systems and methods for delivery of a medicament |
KR102135026B1 (ko) * | 2019-11-22 | 2020-07-17 | 한국지질자원연구원 | 시계열 지표수 흐름 거동 예측방법 |
CN114184693B (zh) * | 2021-10-14 | 2023-10-13 | 重庆医科大学 | 4-羟苯乙酸作为标志物在制备脓毒症脑病的诊断试剂盒中的应用 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4028404A (en) * | 1967-07-31 | 1977-06-07 | Allen & Hanburys Limited | Acetic acid derivatives |
US3998966A (en) * | 1971-11-04 | 1976-12-21 | Syntex Corporation | Anti-inflammatory, analgesic, anti-pyretic and anti-pruritic 6-substituted 2-naphthyl acetic acid derivative-containing compositions and methods of use thereof |
CH576445A5 (de) * | 1972-03-10 | 1976-06-15 | Ciba Geigy Ag | |
CA1041541A (en) * | 1974-01-14 | 1978-10-31 | Giorgio Pifferi | Process for preparing 4-cyclopropyl-methyleneoxy-3-chlorophenylacetic acid and salts thereof |
GB1511645A (en) * | 1974-05-31 | 1978-05-24 | Univ Ife | Sickle cell anaemia treatment |
FR2416214A1 (fr) * | 1978-02-02 | 1979-08-31 | Inst Rech Scient Irs | Derives d'acide naphtyl-1 acetique, leur procede de preparation et leur application therapeutique |
US4282214A (en) * | 1978-07-31 | 1981-08-04 | The Procter & Gamble Company | Phenylacetate anti-inflammatory composition |
AU528532B2 (en) * | 1978-12-18 | 1983-05-05 | Mcniel Laboratories | Acetaminophen analgesic potentiation |
US4470970A (en) * | 1981-07-02 | 1984-09-11 | Burzynski Stanislaw R | Purified antineoplaston fractions and methods of treating neoplastic disease |
US4499299A (en) * | 1981-12-30 | 1985-02-12 | Ici Americas Inc. | Pharmaceutically active phenylcarboxylic acid derivatives |
JPS58194814A (ja) * | 1982-05-11 | 1983-11-12 | Nippon Shinyaku Co Ltd | 免疫調節作用を有する薬剤 |
US4457942A (en) * | 1982-08-20 | 1984-07-03 | Brusilow Saul W | Process for waste nitrogen removal |
DE3440288A1 (de) * | 1984-11-05 | 1986-05-07 | Gergely, Gerhard, Dr.-Ing., Wien | Pharmazeutische zubereitung mit einem gehalt an mindestens einer schleimhautreizenden substanz oder dergleichen, insbesondere profen, sowie verfahren zu ihrer herstellung |
DE3678643D1 (de) * | 1985-08-16 | 1991-05-16 | Procter & Gamble | Partikel mit konstanter wirkstofffreisetzung. |
GB8524421D0 (en) * | 1985-10-03 | 1985-11-06 | Boots Co Plc | Therapeutic agents |
GB8528195D0 (en) * | 1985-11-15 | 1985-12-18 | Boots Co Plc | Therapeutic compositions |
GB8606762D0 (en) * | 1986-03-19 | 1986-04-23 | Boots Co Plc | Therapeutic agents |
CH669523A5 (de) * | 1986-06-25 | 1989-03-31 | Mepha Ag | |
GB8623557D0 (en) * | 1986-10-01 | 1986-11-05 | Boots Co Plc | Therapeutic agents |
US4788220A (en) * | 1987-07-08 | 1988-11-29 | American Home Products Corporation (Del.) | Pediatric ibuprofen compositions |
US4999226A (en) * | 1988-06-01 | 1991-03-12 | Merrell Dow Pharmaceuticals Inc. | Pharmaceutical compositions for piperidinoalkanol-ibuprofen combination |
US5032384A (en) * | 1989-01-27 | 1991-07-16 | Block Drug Company, Inc. | Compositions and method for the treatment of disease |
US4975465A (en) * | 1989-03-28 | 1990-12-04 | American Home Products Corporation | Orally administrable ibuprofen compositions |
NZ234143A (en) * | 1989-06-28 | 1991-10-25 | Mcneil Ppc Inc | Aqueous pharmaceutical suspension formulation for administering substantially insoluble pharmaceutical agents |
GB8920693D0 (en) * | 1989-09-13 | 1989-10-25 | Nicholas Kiwi Pty Ltd | Non-effervescent ibuprofen compositions |
US5204367A (en) * | 1990-02-16 | 1993-04-20 | Harbor Branch Oceanographic Institution, Inc. | Novel antiviral and anti-leukemia terpene hydroquinones and methods of use |
US5244922A (en) * | 1990-09-04 | 1993-09-14 | Burzynski Stanislaw R | Methods for treating viral infections |
WO1993007866A2 (en) * | 1991-10-21 | 1993-04-29 | Dvorit Samid | Compositions and methods for therapy and prevention of cancer, aids, and anemia |
-
1994
- 1994-03-07 US US08/207,521 patent/US5605930A/en not_active Expired - Lifetime
- 1994-10-11 IL IL11125194A patent/IL111251A/en active IP Right Grant
- 1994-10-12 PT PT94930694T patent/PT725635E/pt unknown
- 1994-10-12 EP EP04030912A patent/EP1523982B1/de not_active Expired - Lifetime
- 1994-10-12 AT AT94930694T patent/ATE285760T1/de not_active IP Right Cessation
- 1994-10-12 US US08/633,833 patent/US5852056A/en not_active Expired - Fee Related
- 1994-10-12 DK DK04030912T patent/DK1523982T3/da active
- 1994-10-12 AT AT04030912T patent/ATE388699T1/de not_active IP Right Cessation
- 1994-10-12 EP EP94930694A patent/EP0725635B1/de not_active Expired - Lifetime
- 1994-10-12 AU AU79737/94A patent/AU702051B2/en not_active Ceased
- 1994-10-12 DE DE69434211T patent/DE69434211T2/de not_active Expired - Lifetime
- 1994-10-12 ES ES94930694T patent/ES2233931T3/es not_active Expired - Lifetime
- 1994-10-12 CA CA002173976A patent/CA2173976C/en not_active Expired - Fee Related
- 1994-10-12 JP JP51197795A patent/JP3628694B2/ja not_active Expired - Fee Related
- 1994-10-12 DE DE69435086T patent/DE69435086T2/de not_active Expired - Lifetime
- 1994-10-12 WO PCT/US1994/011492 patent/WO1995010271A2/en active Search and Examination
- 1994-10-12 SI SI9430486T patent/SI1523982T1/sl unknown
- 1994-10-12 NZ NZ275673A patent/NZ275673A/xx not_active IP Right Cessation
- 1994-10-12 ES ES04030912T patent/ES2303624T3/es not_active Expired - Lifetime
- 1994-10-12 PT PT04030912T patent/PT1523982E/pt unknown
-
1995
- 1995-06-07 US US08/484,615 patent/US5883124A/en not_active Expired - Fee Related
- 1995-06-07 US US08/478,264 patent/US5843994A/en not_active Expired - Lifetime
-
2001
- 2001-03-12 JP JP2001069516A patent/JP2001253821A/ja not_active Withdrawn
-
2002
- 2002-10-16 JP JP2002302292A patent/JP2003119130A/ja not_active Withdrawn
-
2005
- 2005-02-28 JP JP2005054744A patent/JP2005139209A/ja not_active Withdrawn
- 2005-02-28 JP JP2005054743A patent/JP2005139208A/ja not_active Withdrawn
- 2005-10-20 HK HK05109253A patent/HK1077204A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69434211D1 (de) | Phenylacetate und derivate, allein oder in kombination mit anderen verbindungen, zur behandlung von neoplastischen und anderen erkrankungen | |
ATE355374T1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
ATE399553T1 (de) | Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen | |
DE69636343D1 (de) | Verwendung von glu-trp dipeptiden zur herstellung eines arzneimittels zur behandlung von verschiedenen gefässneubildung-assozierten erkrankungen | |
DE60216830D1 (de) | Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen | |
PT668763E (pt) | Utilizacao de fenserina para a preparacao de medicamentos para tratar doencas do conhecimento | |
DE69424777T2 (de) | 3,4-diarylchromane zur behandlung von dermatitis | |
DE68912195D1 (de) | Verwendung von Pyrrolicloncarbonsäurealkylestern zur Herstellung eines Arzneimittels zur Behandlung von Ichtyosis. | |
ATE137965T1 (de) | Verwendung von tomoxetine zur behandlung von funktionsstörungen der niedrigen harnwege | |
BR9809678A (pt) | Derivados de triptolìdeo úteis no tratamento de doenças autoimunes | |
DE69111974T2 (de) | Verwendung von Lithium zur Behandlung oder Prophylaxe von Molluscum contagiusum. | |
ITMI922742A0 (it) | Composti ad attivita' terapeutica utili per il trattamento di malattieconnesse ad una carenza di glutatione, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono. | |
ATE120447T1 (de) | Polyamin-derivate als antineoplastische mittel. | |
DE69434002D1 (de) | 2,3 diaryl-1-benzopyrame zur behandlung von dermatitis | |
DK0425109T3 (da) | 3-substitueret-2-oxindolderivater som inhibitorer for interleukin-1-biosyntese | |
ATE245421T1 (de) | Pharmazeutische zusammensetzung welche riluzol und gabapentin enthält zur behandung von motoneuronalen krankheiten | |
ATE201993T1 (de) | Verwendung von olanzapine zur herstellung eines arzneimittels zur behandlung der zerebralen fokalen ischämie | |
MX9704887A (es) | Composiciones farmaceuticas para el tratamiento de trastornos depresivos. | |
IT1229204B (it) | Prodotto farmaceutico analgesico e anti infiammatorio per la cura delle affezioni dell'apparato muscolo scheletrico e metodo per ottenere detto prodotto. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |